The selection of target cell types for X-ALD gene therapy requires a comprehensive understanding of both the natural expression pattern of ABCD1 and the cellular mechanisms underlying disease pathogenesis. This evidence concerns the gene ABCD1 and X-linked adrenoleukodystrophy.